当前位置: 首页 >> 检索结果
221. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.
作者: Andreas Münch.;Johan Bohr.;Stephan Miehlke.;Cecilia Benoni.;Martin Olesen.;Åke Öst.;Lars Strandberg.;Per M Hellström.;Erik Hertervig.;Peter Armerding.;Jiri Stehlik.;Greger Lindberg.;Jan Björk.;Annika Lapidus.;Robert Löfberg.;Ole Bonderup.;Sören Avnström.;Martin Rössle.;Karin Dilger.;Ralph Mueller.;Roland Greinwald.;Curt Tysk.;Magnus Ström.; .
来源: Gut. 2016年65卷1期47-56页
This 1-year study aimed to assess low-dose budesonide therapy for maintenance of clinical remission in patients with collagenous colitis.
222. Long-term risk of colorectal cancer in individuals with serrated polyps.
作者: Øyvind Holme.;Michael Bretthauer.;Tor J Eide.;Else Marit Løberg.;Krzysztof Grzyb.;Magnus Løberg.;Mette Kalager.;Hans-Olov Adami.;Øystein Kjellevold.;Geir Hoff.
来源: Gut. 2015年64卷6期929-36页
Although serrated polyps may be precursors of colorectal cancer (CRC), prospective data on the long-term CRC risk in individuals with serrated polyps are lacking.
223. Virtual portal pressure gradient from anatomic CT angiography.
作者: Xiaolong Qi.;Zhiwei Li.;Jiale Huang.;Yanjie Zhu.;Hao Liu.;Fangyu Zhou.;Changchun Liu.;Chaohui Xiao.;Jinghui Dong.;Yongzhao Zhao.;Mingxin Xu.;Surong Xing.;Weiguo Xu.;Changqing Yang.
来源: Gut. 2015年64卷6期1004-5页 224. Real-time optical diagnosis for diminutive colorectal polyps using narrow-band imaging: the VALID randomised clinical trial.
作者: Tonya Kaltenbach.;Amit Rastogi.;Robert V Rouse.;Kenneth R McQuaid.;Tohru Sato.;Ajay Bansal.;Jon C Kosek.;Roy Soetikno.
来源: Gut. 2015年64卷10期1569-77页
Diminutive (≤ 5 mm) colorectal polyps are common, and overwhelmingly benign. Routinely, after polypectomy, they are examined pathologically to determine the surveillance intervals. Advances in equipment and techniques, such as narrow-band imaging (NBI) colonoscopy, now permit reliable real-time optical diagnosis.
225. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
作者: Niels Vande Casteele.;Reena Khanna.;Barrett G Levesque.;Larry Stitt.;G Y Zou.;Sharat Singh.;Steve Lockton.;Scott Hauenstein.;Linda Ohrmund.;Gordon R Greenberg.;Paul J Rutgeerts.;Ann Gils.;William J Sandborn.;Séverine Vermeire.;Brian G Feagan.
来源: Gut. 2015年64卷10期1539-45页
Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an assay sensitive for identification of ATI in the presence of infliximab.
226. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
作者: Silvio Danese.;Janusz Rudziński.;Wolfgang Brandt.;Jean-Louis Dupas.;Laurent Peyrin-Biroulet.;Yoram Bouhnik.;Dariusz Kleczkowski.;Peter Uebel.;Milan Lukas.;Mikael Knutsson.;Fredrik Erlandsson.;Mark Berner Hansen.;Satish Keshav.
来源: Gut. 2015年64卷2期243-9页
Interleukin-13 (IL-13) has been implicated as a key driver of UC. This trial evaluates the efficacy and safety of tralokinumab, an IL-13-neutralising antibody, as add-on therapy in adults with moderate-to-severe UC despite standard treatments.
227. Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial.
作者: Satoshi Mochizuki.;Noriya Uedo.;Ichiro Oda.;Kazuhiro Kaneko.;Yorimasa Yamamoto.;Takeshi Yamashina.;Haruhisa Suzuki.;Shinya Kodashima.;Tomonori Yano.;Nobutake Yamamichi.;Osamu Goto.;Takeshi Shimamoto.;Mitsuhiro Fujishiro.;Kazuhiko Koike.; .
来源: Gut. 2015年64卷3期397-405页
To clarify the effectiveness of second-look endoscopy (SLE) at preventing bleeding after gastric endoscopic submucosal dissection (ESD).
228. A phase II study of laquinimod in Crohn's disease.
作者: Geert D'Haens.;William J Sandborn.;Jean Frederic Colombel.;Paul Rutgeerts.;Kurt Brown.;Hadas Barkay.;Anat Sakov.;Asi Haviv.;Brian G Feagan.; .
来源: Gut. 2015年64卷8期1227-35页
Laquinimod is an oral therapeutic agent under investigation for the treatment of Crohn's disease (CD), Huntington's disease, lupus nephritis and multiple sclerosis. This dose escalation study evaluated the safety and efficacy of laquinimod as induction therapy in patients with active moderate-severe CD.
229. Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy.
作者: Jasmijn F Haanstra.;Abdul Al-Toma.;Evelien Dekker.;Steven A L W Vanhoutvin.;Fokko M Nagengast.;Elisabeth M Mathus-Vliegen.;Monique E van Leerdam.;Wouter H de Vos tot Nederveen Cappel.;Silvia Sanduleanu.;Roeland A Veenendaal.;Annemieke Cats.;Hans F A Vasen.;Jan H Kleibeuker.;Jan J Koornstra.
来源: Gut. 2015年64卷10期1578-83页
The aim was to determine the prevalence of small-bowel neoplasia in asymptomatic patients with Lynch syndrome (LS) by video capsule endoscopy (VCE).
230. Long-term lifestyle changes after colorectal cancer screening: randomised controlled trial.
作者: Paula Berstad.;Magnus Løberg.;Inger Kristin Larsen.;Mette Kalager.;Øyvind Holme.;Edoardo Botteri.;Michael Bretthauer.;Geir Hoff.
来源: Gut. 2015年64卷8期1268-76页
There is uncertainty whether cancer screening affects participant incentives for favourable lifestyle. The present study investigates long-term effects of colorectal cancer (CRC) screening on lifestyle changes.
231. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants.
作者: Tanja Jaeggi.;Guus A M Kortman.;Diego Moretti.;Christophe Chassard.;Penny Holding.;Alexandra Dostal.;Jos Boekhorst.;Harro M Timmerman.;Dorine W Swinkels.;Harold Tjalsma.;Jane Njenga.;Alice Mwangi.;Jane Kvalsvig.;Christophe Lacroix.;Michael B Zimmermann.
来源: Gut. 2015年64卷5期731-42页
In-home iron fortification for infants in developing countries is recommended for control of anaemia, but low absorption typically results in >80% of the iron passing into the colon. Iron is essential for growth and virulence of many pathogenic enterobacteria. We determined the effect of high and low dose in-home iron fortification on the infant gut microbiome and intestinal inflammation.
232. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
作者: Christophe Hézode.;Gideon M Hirschfield.;Wayne Ghesquiere.;William Sievert.;Maribel Rodriguez-Torres.;Stephen D Shafran.;Paul J Thuluvath.;Harvey A Tatum.;Imam Waked.;Gamal Esmat.;Eric J Lawitz.;Vinod K Rustgi.;Stanislas Pol.;Nina Weis.;Paul J Pockros.;Marc Bourlière.;Lawrence Serfaty.;John M Vierling.;Michael W Fried.;Ola Weiland.;Maurizia R Brunetto.;Gregory T Everson.;Stefan Zeuzem.;Paul Y Kwo.;Mark Sulkowski.;Norbert Bräu.;Dennis Hernandez.;Fiona McPhee.;Megan Wind-Rotolo.;Zhaohui Liu.;Stephanie Noviello.;Eric A Hughes.;Philip D Yin.;Steven Schnittman.
来源: Gut. 2015年64卷6期948-56页
To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin.
233. Abnormal fibre usage in UC in remission.
作者: Sally L James.;Claus T Christophersen.;Anthony R Bird.;Michael A Conlon.;Ourania Rosella.;Peter R Gibson.;Jane G Muir.
来源: Gut. 2015年64卷4期562-70页
Colonic fermentation in patients with UC in remission was compared with that in matched healthy subjects on habitual diets and when dietary fibre was increased.
234. Diets that differ in their FODMAP content alter the colonic luminal microenvironment.
作者: Emma P Halmos.;Claus T Christophersen.;Anthony R Bird.;Susan J Shepherd.;Peter R Gibson.;Jane G Muir.
来源: Gut. 2015年64卷1期93-100页
A low FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) diet reduces symptoms of IBS, but reduction of potential prebiotic and fermentative effects might adversely affect the colonic microenvironment. The effects of a low FODMAP diet with a typical Australian diet on biomarkers of colonic health were compared in a single-blinded, randomised, cross-over trial.
235. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
作者: Pauline Arends.;Milan J Sonneveld.;Roeland Zoutendijk.;Ivana Carey.;Ashley Brown.;Massimo Fasano.;David Mutimer.;Katja Deterding.;Jurriën G P Reijnders.;Ye Oo.;Jörg Petersen.;Florian van Bömmel.;Robert J de Knegt.;Teresa Santantonio.;Thomas Berg.;Tania M Welzel.;Heiner Wedemeyer.;Maria Buti.;Pierre Pradat.;Fabien Zoulim.;Bettina Hansen.;Harry L A Janssen.; .
来源: Gut. 2015年64卷8期1289-95页
Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk scores during ETV treatment in an ethnically diverse Western population.
236. Colon capsule versus CT colonography in patients with incomplete colonoscopy: a prospective, comparative trial.
作者: Cristiano Spada.;Cesare Hassan.;Brunella Barbaro.;Franco Iafrate.;Paola Cesaro.;Lucio Petruzziello.;Leonardo Minelli Grazioli.;Carlo Senore.;Gabriella Brizi.;Isabella Costamagna.;Giuseppe Alvaro.;Marcella Iannitti.;Marco Salsano.;Maria Ciolina.;Andrea Laghi.;Lorenzo Bonomo.;Guido Costamagna.
来源: Gut. 2015年64卷2期272-81页
In case of incomplete colonoscopy, several radiologic methods have traditionally been used, but more recently, capsule endoscopy was also shown to be accurate. Aim of this study was to compare colon capsule endoscopy (CCE) and CT colonography (CTC) in a prospective cohort of patients with incomplete colonoscopy.
237. Preliminary report: modulation of parasympathetic nervous system tone influences oesophageal pain hypersensitivity.
作者: Claude Botha.;Adam D Farmer.;Matias Nilsson.;Christina Brock.;Ana D Gavrila.;Asbjørn Mohr Drewes.;Charles H Knowles.;Qasim Aziz.
来源: Gut. 2015年64卷4期611-7页
Autonomic nervous system dysfunction has been implicated in visceral hypersensitivity. However, the specific contribution of the parasympathetic nervous system (PNS) is unclear. We aimed to determine whether physiological and pharmacological manipulation of parasympathetic tone influences the development of hypersensitivity in a validated model of acid-induced oesophageal pain.
238. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
作者: Tim Wyant.;Tim Leach.;Serap Sankoh.;Yuemei Wang.;Jonathan Paolino.;Marcela F Pasetti.;Brian G Feagan.;Asit Parikh.
来源: Gut. 2015年64卷1期77-83页
The α4β7 integrin monoclonal antibody vedolizumab is hypothesised to be gut selective. Effects of vedolizumab on immune responses to parenterally or enterally administered antigens were investigated.
239. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
作者: Chen-Hua Liu.;Chun-Jen Liu.;Chung-Feng Huang.;Jou-Wei Lin.;Chia-Yen Dai.;Cheng-Chao Liang.;Jee-Fu Huang.;Peir-Haur Hung.;Hung-Bin Tsai.;Meng-Kun Tsai.;Chih-Yuan Lee.;Shih-I Chen.;Sheng-Shun Yang.;Tung-Hung Su.;Hung-Chih Yang.;Pei-Jer Chen.;Ding-Shinn Chen.;Wan-Long Chuang.;Ming-Lung Yu.;Jia-Horng Kao.
来源: Gut. 2015年64卷2期303-11页
Data comparing the efficacy and safety of combination therapy with peginterferon plus low-dose ribavirin and peginterferon monotherapy in treatment-naive haemodialysis patients with hepatitis C virus genotype 2 (HCV-2) infection are limited.
240. Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals.
作者: Sebastian Lunemann.;David F G Malone.;Jan Grabowski.;Kerstin Port.;Vivien Béziat.;Birgit Bremer.;Karl-Johan Malmberg.;Michael P Manns.;Johan K Sandberg.;Markus Cornberg.;Hans-Gustaf Ljunggren.;Heiner Wedemeyer.;Niklas K Björkström.
来源: Gut. 2015年64卷3期469-82页
Although hepatitis delta is considered an immune-mediated disease, adaptive immune responses to hepatitis delta virus (HDV) are hardly detectable. Thus, the role of other immune responses, including those mediated by natural killer (NK) cells, must be considered in HDV pathogenesis and in treatments with immune-stimulating agents such as interferon (IFN)α. However, the phenotype and function of NK cells in chronic HDV infection, or in HDV-infected individuals undergoing IFNα treatment, have not been extensively studied.
|